Palatin Technologies, Inc. (PTN)

2,0500 -0,0300 (-1,44%) Al cierre: 04:00PM EDT

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200
https://palatin.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 34

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Carl Spana Ph.D.	Co-Founder, President, CEO & Director	979k	N/A	1962
Mr. Stephen T. Wills CPA, MST	CFO, COO, Executive VP, Treasurer & Secretary	910,55k	N/A	1957
Burns McClellan	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Stephen A. Slusher Esq.	Chief Legal Officer	N/A	N/A	N/A
Dr. Michael B. Raizman M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. James E. Hattersley	Senior Vice President of Business Development	N/A	N/A	1960
Mr. John Dodd Ph.D.	Senior Vice President of Preclinical Development	N/A	N/A	N/A
Mr. Robert Jordan	Senior Vice President of Program Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de Palatin Technologies, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.